It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Serratus intercostal fascial plane block (SIFPB) has emerged as an alternative to paravertebral block in breast surgery. It involves the administration of high volumes and doses of local anesthetics (LA) that can potentially reach toxic levels. Ropivacaine is widely used in thoraco-fascial blocks; however, there is no information on the plasma concentrations attained after SIPFB and whether they are associated with cardiotoxicity. Plasma concentrations of ropivacaine and its electrophysiological effects were evaluated in eight pigs after bilateral SIFPB with ropivacaine in doses of 3 mg/kg. Plasma concentrations, electrophysiological and hemodynamic parameters were measured sequentially for the following 180 min until the end of the study. The area under the curve, the maximum plasma concentration (Cmax) and the time to reach Cmax (tmax) were calculated. The median arterial ropivacaine concentration Cmax was, 2.34 [1.40 to 3.74] µg/ml. The time to reach the highest concentration was 15 [10 to 20] min. Twenty-five percent of the animals had arterial concentrations above the lower limit concentration of ropivacaine for LA systemic toxicity (3.4 µg/ml). No alterations were observed in the electrophysiological or electrocardiographic parameters except for a prolongation of the QTc interval, from 489 ± 30 to 544 ± 44 ms (Δ11.38 ± 6%), P = 0.01. Hemodynamic parameters remained in the physiological range throughout the study. SIFPB with ropivacaine in doses of 3 mg/kg has reached potentially toxic levels, however, it has not been associated with adverse electrophysiological or hemodynamic effects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Complutense University, Department of Forensic Medicine, Psychiatry and Pathology, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667); Hospital General Universitario Gregorio Marañón, Department of Anesthesiology, Madrid, Spain (GRID:grid.410526.4) (ISNI:0000 0001 0277 7938)
2 Hospital General Universitario Gregorio Marañón, Department of Anesthesiology, Madrid, Spain (GRID:grid.410526.4) (ISNI:0000 0001 0277 7938)
3 Complutense University, Department of Forensic Medicine, Psychiatry and Pathology, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667)
4 Hospital General Universitario Gregorio Marañón, Madrid, Spain (GRID:grid.410526.4) (ISNI:0000 0001 0277 7938)
5 University CEU-San Pablo, Hospital Monteprincipe, Grupo HM Hospitales, Madrid, Spain (GRID:grid.8461.b) (ISNI:0000 0001 2159 0415)